Faruqi & Faruqi Investigates Inovio Investor Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 11 2026
0mins
Should l Buy INO?
Source: PRnewswire
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Inovio Pharmaceuticals for potential claims related to investor losses incurred between October 10, 2023, and December 26, 2025, highlighting the firm's commitment to protecting investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly via phone at 877-247-4292 or 212-983-9330, aiming to assist them in understanding their legal options.
- Class Action Reminder: The firm reminds investors that April 7, 2026, is the deadline to seek lead plaintiff status in the federal securities class action filed against Inovio, underscoring the importance of timely action for affected parties.
- Potential Claim Risks: As the investigation progresses, the potential claim risks facing Inovio could impact the company's reputation and future stock price, reflecting market concerns regarding the company's compliance and governance practices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.730
Low
3.00
Averages
7.33
High
13.00
Current: 1.730
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inovio Pharmaceuticals to Announce Q4 Earnings on March 12
- Earnings Announcement Schedule: Inovio Pharmaceuticals is set to release its Q4 2023 earnings report on March 12 after market close, with consensus EPS estimates at -$0.36, indicating challenges in profitability.
- Historical Performance Review: Over the past year, Inovio has beaten EPS estimates 50% of the time and revenue estimates only 25% of the time, suggesting significant volatility in performance that may affect investor confidence.
- Expectation Revision Dynamics: In the last three months, there has been one upward revision and no downward adjustments to EPS estimates, reflecting a cautiously optimistic outlook from analysts regarding the company's future performance, though market reactions remain to be seen.
- FDA Review Impact: Inovio's respiratory papillomatosis asset was denied accelerated review, leading to a drop in stock price, highlighting the significant impact of FDA reviews on the company's growth potential.
See More
Multiple Companies Face Class Action Lawsuits
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors of class action lawsuits filed against BlackRock TCP Capital Corp., Oracle Corporation, Paysafe Limited, and Inovio Pharmaceuticals, urging investors to file lead plaintiff motions by the specified deadlines to protect their legal rights.
- BlackRock TCP Lawsuit Details: The lawsuit alleges that BlackRock failed to timely disclose the true valuation of investments and net asset value from November 2024 to January 2026, potentially exposing investors to significant losses, with a lead plaintiff deadline of April 6, 2026.
- Oracle Litigation Risks: In the class action from June to December 2025, Oracle investors were informed that the company's AI infrastructure strategy would lead to massive capital expenditures without corresponding revenue growth, with the lead plaintiff deadline also set for April 6, 2026.
- Issues with Paysafe and Inovio: Paysafe's lawsuit highlights significant reliance on high-risk clients that could negatively impact revenue growth, while Inovio faces challenges in timely submitting a critical application to the FDA due to manufacturing deficiencies, both with lead plaintiff deadlines of April 7, 2026.
See More
Faruqi & Faruqi Investigates Potential Claims Against Inovio Pharmaceuticals
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, particularly for investors who purchased or acquired securities between October 10, 2023, and December 26, 2025, aiming to protect investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, ensuring timely legal support for investors.
- Class Action Deadline: Investors should note that the deadline to seek lead plaintiff status in the federal securities class action against Inovio is April 7, 2026, a critical date that may affect their rights to claim.
- Law Firm Background: Faruq & Faruqi, LLP is a leading national securities law firm focused on protecting investor rights through investigations and litigation, demonstrating its expertise and influence in the field of securities law.
See More
Multiple Companies Facing Class Action Lawsuits
- Oracle Lawsuit: Oracle Corporation is facing a class action lawsuit for the period from June 12 to December 16, 2025, due to its AI infrastructure strategy leading to significant capital expenditure increases, which could severely impact its debt and credit rating, with investor losses expected to exceed $50,000.
- Paysafe Risks: Paysafe Limited is being sued for the period from March 4 to November 12, 2025, for failing to disclose significant exposure to a single high-risk client in its e-commerce business, which is likely to negatively impact its revenue growth and may prevent it from meeting its financial guidance for fiscal year 2025.
- Inovio Pharmaceuticals Issues: Inovio Pharmaceuticals, Inc. is facing a class action lawsuit for the period from October 10, 2023, to December 26, 2025, due to deficiencies in manufacturing its CELLECTRA device, which is expected to hinder its ability to submit the INO-3107 BLA to the FDA by the second half of 2024, affecting its regulatory and commercial prospects.
- Kyndryl Financial Misstatements: Kyndryl Holdings, Inc. is being sued for the period from August 7, 2024, to February 9, 2026, due to materially misstated financial statements, which are expected to prevent timely filing of its Quarterly Report for the quarter ended December 31, 2025, raising concerns about its business outlook.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Inovio Pharmaceuticals and certain executives in the Eastern District of Pennsylvania, representing investors who purchased Inovio securities between October 2023 and December 2025, seeking damages for violations of federal securities laws.
- False Statements Uncovered: The lawsuit alleges that Inovio made materially false and misleading statements throughout the class period, failing to disclose manufacturing deficiencies in its CELLECTRA device, which delayed the submission of the INO-3107 BLA to the FDA until mid-2025, undermining investor confidence.
- Stock Price Volatility: Following the announcement of the delayed BLA submission on August 9, 2024, Inovio's stock price fell by 3.1% to close at $8.44 per share; subsequently, on December 29, 2025, the stock plummeted by 24.45% to $1.73 per share after the FDA accepted the BLA for standard review instead of accelerated review.
- Investor Rights at Stake: The lawsuit highlights significant economic losses suffered by investors due to Inovio's misleading statements, with Pomerantz LLP, a leading firm in securities class action litigation, committed to advocating for the rights of affected investors and seeking compensation.
See More
Inovio Pharmaceuticals Shareholder Notice Issued
- Lawsuit Notice Issued: The Gross Law Firm has issued a notice to shareholders of Inovio Pharmaceuticals, encouraging those who purchased shares between October 10, 2023, and December 26, 2025, to contact the firm regarding potential lead plaintiff status.
- Allegations Overview: The complaint alleges that Inovio made materially false or misleading statements during the class period, particularly regarding deficiencies in the manufacturing of its CELLECTRA device, which jeopardizes the timeline for submitting INO-3107 to the FDA.
- Critical Deadline: Shareholders must register by April 7, 2026, to participate in the class action, emphasizing the urgency of the legal process and the potential impact on their rights to claim damages.
- No Cost Participation: Once registered, shareholders will receive portfolio monitoring updates throughout the case lifecycle, and participation incurs no costs, highlighting the accessibility and transparency of legal services offered by the firm.
See More
Inovio Pharmaceuticals to Announce Q4 Earnings on March 12
- Earnings Announcement Schedule: Inovio Pharmaceuticals is set to release its Q4 2023 earnings report on March 12 after market close, with consensus EPS estimates at -$0.36, indicating challenges in profitability.
- Historical Performance Review: Over the past year, Inovio has beaten EPS estimates 50% of the time and revenue estimates only 25% of the time, suggesting significant volatility in performance that may affect investor confidence.
- Expectation Revision Dynamics: In the last three months, there has been one upward revision and no downward adjustments to EPS estimates, reflecting a cautiously optimistic outlook from analysts regarding the company's future performance, though market reactions remain to be seen.
- FDA Review Impact: Inovio's respiratory papillomatosis asset was denied accelerated review, leading to a drop in stock price, highlighting the significant impact of FDA reviews on the company's growth potential.
See More
Multiple Companies Face Class Action Lawsuits
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors of class action lawsuits filed against BlackRock TCP Capital Corp., Oracle Corporation, Paysafe Limited, and Inovio Pharmaceuticals, urging investors to file lead plaintiff motions by the specified deadlines to protect their legal rights.
- BlackRock TCP Lawsuit Details: The lawsuit alleges that BlackRock failed to timely disclose the true valuation of investments and net asset value from November 2024 to January 2026, potentially exposing investors to significant losses, with a lead plaintiff deadline of April 6, 2026.
- Oracle Litigation Risks: In the class action from June to December 2025, Oracle investors were informed that the company's AI infrastructure strategy would lead to massive capital expenditures without corresponding revenue growth, with the lead plaintiff deadline also set for April 6, 2026.
- Issues with Paysafe and Inovio: Paysafe's lawsuit highlights significant reliance on high-risk clients that could negatively impact revenue growth, while Inovio faces challenges in timely submitting a critical application to the FDA due to manufacturing deficiencies, both with lead plaintiff deadlines of April 7, 2026.
See More
Faruqi & Faruqi Investigates Potential Claims Against Inovio Pharmaceuticals
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, particularly for investors who purchased or acquired securities between October 10, 2023, and December 26, 2025, aiming to protect investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, ensuring timely legal support for investors.
- Class Action Deadline: Investors should note that the deadline to seek lead plaintiff status in the federal securities class action against Inovio is April 7, 2026, a critical date that may affect their rights to claim.
- Law Firm Background: Faruq & Faruqi, LLP is a leading national securities law firm focused on protecting investor rights through investigations and litigation, demonstrating its expertise and influence in the field of securities law.
See More
Multiple Companies Facing Class Action Lawsuits
- Oracle Lawsuit: Oracle Corporation is facing a class action lawsuit for the period from June 12 to December 16, 2025, due to its AI infrastructure strategy leading to significant capital expenditure increases, which could severely impact its debt and credit rating, with investor losses expected to exceed $50,000.
- Paysafe Risks: Paysafe Limited is being sued for the period from March 4 to November 12, 2025, for failing to disclose significant exposure to a single high-risk client in its e-commerce business, which is likely to negatively impact its revenue growth and may prevent it from meeting its financial guidance for fiscal year 2025.
- Inovio Pharmaceuticals Issues: Inovio Pharmaceuticals, Inc. is facing a class action lawsuit for the period from October 10, 2023, to December 26, 2025, due to deficiencies in manufacturing its CELLECTRA device, which is expected to hinder its ability to submit the INO-3107 BLA to the FDA by the second half of 2024, affecting its regulatory and commercial prospects.
- Kyndryl Financial Misstatements: Kyndryl Holdings, Inc. is being sued for the period from August 7, 2024, to February 9, 2026, due to materially misstated financial statements, which are expected to prevent timely filing of its Quarterly Report for the quarter ended December 31, 2025, raising concerns about its business outlook.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Inovio Pharmaceuticals and certain executives in the Eastern District of Pennsylvania, representing investors who purchased Inovio securities between October 2023 and December 2025, seeking damages for violations of federal securities laws.
- False Statements Uncovered: The lawsuit alleges that Inovio made materially false and misleading statements throughout the class period, failing to disclose manufacturing deficiencies in its CELLECTRA device, which delayed the submission of the INO-3107 BLA to the FDA until mid-2025, undermining investor confidence.
- Stock Price Volatility: Following the announcement of the delayed BLA submission on August 9, 2024, Inovio's stock price fell by 3.1% to close at $8.44 per share; subsequently, on December 29, 2025, the stock plummeted by 24.45% to $1.73 per share after the FDA accepted the BLA for standard review instead of accelerated review.
- Investor Rights at Stake: The lawsuit highlights significant economic losses suffered by investors due to Inovio's misleading statements, with Pomerantz LLP, a leading firm in securities class action litigation, committed to advocating for the rights of affected investors and seeking compensation.
See More
Inovio Pharmaceuticals Shareholder Notice Issued
- Lawsuit Notice Issued: The Gross Law Firm has issued a notice to shareholders of Inovio Pharmaceuticals, encouraging those who purchased shares between October 10, 2023, and December 26, 2025, to contact the firm regarding potential lead plaintiff status.
- Allegations Overview: The complaint alleges that Inovio made materially false or misleading statements during the class period, particularly regarding deficiencies in the manufacturing of its CELLECTRA device, which jeopardizes the timeline for submitting INO-3107 to the FDA.
- Critical Deadline: Shareholders must register by April 7, 2026, to participate in the class action, emphasizing the urgency of the legal process and the potential impact on their rights to claim damages.
- No Cost Participation: Once registered, shareholders will receive portfolio monitoring updates throughout the case lifecycle, and participation incurs no costs, highlighting the accessibility and transparency of legal services offered by the firm.
See More
